Who
Michael T. Constantino
Director
Company insider
Files Form 4 as: Director, Humacyte; Director, 9 Meters Biopharma.
In numbers
- Trades disclosed
- 24
- Buys
- 11
- Sells
- 0
- Bought
- $210K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 6 Jul 2020
- Last trade
- 11 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 12 Jun 2026 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | HUMA HumacyteBiotechnology | SEC FORM 4 Bought | $9,84011,000 at $0.8945 | filing |
| 18 May 2026filed 20 May 2026 | HUMA HumacyteBiotechnology | SEC FORM 4 Bought | $9,79011,000 at $0.89 | filing |
| 12 Jun 2025filed 16 Jun 2025 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 7 Apr 2025filed 8 Apr 2025 | HUMA HumacyteBiotechnology | SEC FORM 4 Bought | $20K16,000 at $1.26 | filing |
| 4 Dec 2024filed 4 Dec 2024 | HUMA HumacyteBiotechnology | SEC FORM 4 Bought | $20K4,600 at $4.39 | filing |
| 15 Aug 2024filed 15 Aug 2024 | HUMA HumacyteBiotechnology | SEC FORM 4 Bought | $19K3,100 at $6.29 | filing |
| 13 Jun 2024filed 17 Jun 2024 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 15 Jun 2023filed 16 Jun 2023 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,500 at $0.00 | filing |
| 18 May 2023filed 19 May 2023 | HUMA HumacyteBiotechnology | SEC FORM 4 Bought | $20K4,750 at $4.18 | filing |
| 29 Mar 2023filed 31 Mar 2023 | 9 Meters Biopharma | SEC FORM 4 Code A | —7,885 | filing |
| 22 Jun 2022filed 23 Jun 2022 | 9 Meters Biopharmaoption or derivative | SEC FORM 4 Code A | —142,509 at $0.00 | filing |
| 9 Jun 2022filed 13 Jun 2022 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,500 at $0.00 | filing |
| 23 May 2022filed 24 May 2022 | 9 Meters Biopharma | SEC FORM 4 Bought | $7,68016,000 at $0.48 | filing |
| 23 May 2022filed 24 May 2022 | HUMA HumacyteBiotechnology | SEC FORM 4 Bought | $9,6602,000 at $4.83 | filing |
| 22 Nov 2021filed 24 Nov 2021 | HUMA HumacyteBiotechnology | SEC FORM 4 Bought | $2,166200 at $10.83 | filing |
| 22 Nov 2021filed 24 Nov 2021 | HUMA HumacyteBiotechnology | SEC FORM 4 Bought | $25K2,300 at $10.79 | filing |
| 13 Oct 2021filed 15 Oct 2021 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 24 Aug 2021filed 26 Aug 2021 | 9 Meters Biopharma | SEC FORM 4 Bought | $21K18,000 at $1.14 | filing |
News
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by HospitalsHUMA · manilatimes.net · 15 Oct 2026
0 headlines in the last 90 days name Michael T. Constantino; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.